NASDAQ:HCM HUTCHMED (HCM) Stock Price, News & Analysis $14.62 -0.47 (-3.11%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$14.54 -0.08 (-0.58%) As of 08:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HUTCHMED Stock (NASDAQ:HCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HUTCHMED alerts:Sign Up Key Stats Today's Range$14.50▼$14.8450-Day Range$13.09▼$16.7552-Week Range$12.84▼$21.92Volume44,633 shsAverage Volume106,068 shsMarket Capitalization$2.55 billionP/E RatioN/ADividend YieldN/APrice Target$19.00Consensus RatingHold Company OverviewHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Read More… Remove Ads HUTCHMED Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreHCM MarketRank™: HUTCHMED scored higher than 54% of companies evaluated by MarketBeat, and ranked 513th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingHUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHUTCHMED has received no research coverage in the past 90 days.Read more about HUTCHMED's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth812.50% Earnings GrowthEarnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.Price to Book Value per Share RatioHUTCHMED has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about HUTCHMED's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in HUTCHMED has recently decreased by 7.32%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHUTCHMED does not currently pay a dividend.Dividend GrowthHUTCHMED does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of HUTCHMED has been sold short.Short Interest Ratio / Days to CoverHUTCHMED has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in HUTCHMED has recently decreased by 7.32%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News Sentiment0.41 News SentimentHUTCHMED has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for HUTCHMED this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for HCM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added HUTCHMED to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HUTCHMED insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of HUTCHMED is held by insiders.Percentage Held by InstitutionsOnly 8.82% of the stock of HUTCHMED is held by institutions.Read more about HUTCHMED's insider trading history. Receive HCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter. Email Address HCM Stock News HeadlinesHUTCHMED (NASDAQ:HCM) Upgraded by StockNews.com to Buy RatingMarch 22, 2025 | americanbankingnews.comHutchmed says NDA for Tazverik granted conditional approval in ChinaMarch 21, 2025 | markets.businessinsider.comUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 40-year career. During the presentation, Larry reveals a strategy every trader and investor needs to understand. He calls it “Bitcoin Skimming.”March 26, 2025 | Brownstone Research (Ad)HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular LymphomaMarch 21, 2025 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Dermata Therapeutics (DRMA), HUTCHMED (HCM)March 21, 2025 | markets.businessinsider.comHUTCHMED and Innovent report success in renal cancer studyMarch 20, 2025 | investing.comIntended Retirement of Independent Non-executive Directors and changes of composition of board committeesMarch 20, 2025 | globenewswire.comHutchmed reports FY24 EPS 22c vs. 59c last yearMarch 20, 2025 | markets.businessinsider.comSee More Headlines HCM Stock Analysis - Frequently Asked Questions How have HCM shares performed this year? HUTCHMED's stock was trading at $14.41 at the beginning of 2025. Since then, HCM stock has increased by 1.5% and is now trading at $14.62. View the best growth stocks for 2025 here. When did HUTCHMED IPO? HUTCHMED (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers. Who are HUTCHMED's major shareholders? Top institutional investors of HUTCHMED include Schroder Investment Management Group (1.59%), Millennium Management LLC (0.12%), Renaissance Technologies LLC (0.11%) and Amundi (0.10%). How do I buy shares of HUTCHMED? Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HUTCHMED own? Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), General Electric (GE) and ServiceNow (NOW). Company Calendar Today3/25/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCM CIK1648257 Webwww.chi-med.com Phone852-2121-3888Fax852-2128-1778Employees1,988Year Founded2000Price Target and Rating Average Stock Price Target$19.00 High Stock Price Target$19.00 Low Stock Price Target$19.00 Potential Upside/Downside+30.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.07 Current Ratio2.81 Quick Ratio2.68 Sales & Book Value Annual Sales$630.20 million Price / Sales4.04 Cash Flow$0.60 per share Price / Cash Flow24.51 Book Value$4.27 per share Price / Book3.42Miscellaneous Outstanding Shares174,320,000Free Float168,044,000Market Cap$2.55 billion OptionableNot Optionable Beta0.77 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:HCM) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.